Elicio Therapeutics reported net income of -$8.22M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||
| Revenue | 1.46M | 25.94M | 1.65M | 0.65M | ||||||||||||||||||||||
| Cost of RevenueCost of Rev | 0.43M | |||||||||||||||||||||||||
| Gross Profit | 1.46M | 25.51M | ||||||||||||||||||||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 13.29M | 6.67M | 11.67M | 5.04M | 4.59M | 4.29M | 5.48M | 4.94M | 7.26M | 6.16M | 7.56M | 8.18M | 7.21M | 10.71M | 7.78M | 7.01M | 5.04M | 5.08M | 6.76M | 6.81M | ||||||
| Selling, General & AdministrativeSG&A | 3.93M | 4.21M | 4.47M | 1.19M | 1.18M | 1.67M | 2.32M | 2.83M | 3.51M | 3.23M | 2.68M | 2.74M | 3.14M | 2.77M | 2.96M | 3.08M | 3.01M | 3.76M | 3.85M | 3.62M | ||||||
| Restructuring CostsRestructuring | 2.80M | 3.15M | ||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | 0.43M | -3.15M | -0.10M | 0.10M | 0.00M | |||||||||||||||||||||
| Operating ExpensesOpex | 17.22M | 11.31M | 16.13M | 6.23M | 5.77M | 5.96M | 7.80M | 7.78M | 10.77M | 9.39M | 10.24M | 10.92M | 10.34M | 13.48M | 10.74M | 10.09M | 8.04M | 8.84M | 10.60M | 10.43M | ||||||
| Operating IncomeOp. Inc | -15.76M | 14.63M | -14.48M | -6.23M | -5.77M | -5.96M | -7.80M | -7.78M | -10.77M | -9.39M | -10.24M | -10.92M | -10.34M | -13.48M | -10.74M | -10.09M | -8.04M | -8.84M | -10.60M | -10.43M | ||||||
| EBIT | -15.76M | 14.63M | -14.48M | -6.23M | -5.77M | -5.96M | -7.80M | -7.78M | -10.77M | -9.39M | -10.24M | -10.92M | -10.34M | -13.48M | -10.74M | -10.09M | -8.04M | -8.84M | -10.60M | -10.43M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 1.07M | 1.08M | 0.09M | 0.34M | 0.71M | 0.00M | 0.00M | 0.04M | 0.05M | 0.14M | 0.23M | 0.18M | 0.19M | 0.43M | 0.34M | 0.41M | 0.41M | |||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.06M | 0.01M | 0.04M | 0.25M | 0.07M | 0.15M | 0.14M | 0.18M | 0.21M | 0.17M | 0.20M | 0.16M | 0.14M | ||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.20M | 0.11M | -0.36M | -0.66M | 0.11M | 0.60M | -0.03M | 0.00M | 0.15M | -0.01M | -0.00M | 0.01M | 0.01M | 0.00M | ||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.05M | 0.26M | 0.24M | -1.07M | -1.43M | -0.69M | -0.22M | 0.22M | 0.11M | 0.44M | -1.59M | 3.69M | -8.49M | -0.53M | -0.47M | -0.47M | -2.04M | 1.12M | -1.22M | 2.21M | ||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -15.76M | 14.63M | -14.48M | -7.30M | -6.84M | -6.00M | -8.14M | -8.45M | -10.53M | -9.32M | -10.13M | -10.84M | -10.30M | -13.71M | -10.70M | -10.12M | -8.27M | -9.18M | -10.85M | -10.70M | ||||||
| Profit After TaxPAT | -15.70M | 14.89M | -7.06M | -7.30M | -7.20M | -6.65M | -8.03M | -7.56M | -10.68M | -9.12M | -11.83M | -7.23M | -18.84M | -14.00M | -11.21M | -10.56M | -10.08M | -7.72M | -11.82M | -8.22M | ||||||
| Equity Income | 0.03M | -0.17M | 0.01M | 0.13M | 0.01M | |||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -15.76M | 14.63M | -14.48M | -7.30M | -6.84M | -6.00M | -8.14M | -8.45M | -10.53M | -9.32M | -10.13M | -10.84M | -10.30M | -13.71M | -10.70M | -10.12M | -8.27M | -9.18M | -10.85M | -10.70M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -15.76M | 14.63M | -14.48M | -7.30M | -6.84M | -6.00M | -8.14M | -8.45M | -10.53M | -9.32M | -10.13M | -10.84M | -10.30M | -13.71M | -10.70M | -10.12M | -8.27M | -9.18M | -10.85M | -10.70M | ||||||
| Income towards Parent CompanyParent Net Inc | -15.76M | 14.63M | -14.48M | -7.30M | -6.84M | -6.00M | -8.14M | -8.45M | -10.53M | -9.32M | -10.13M | -10.84M | -10.30M | -13.71M | -10.70M | -10.12M | -8.27M | -9.18M | -10.85M | -10.70M | ||||||
| Net Income towards Common StockholdersNet Income | -15.76M | 14.63M | -14.48M | -7.30M | -6.84M | -6.00M | -8.14M | -8.45M | -10.53M | -9.32M | -10.13M | -10.84M | -10.30M | -13.71M | -10.70M | -10.12M | -8.27M | -9.18M | -10.85M | -10.70M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -5.28 | 5.18 | -4.83 | -2.44 | -2.27 | -2.00 | -2.70 | -2.73 | -1.26 | -1.84 | -0.99 | -0.96 | -0.76 | -1.12 | -0.83 | -0.63 | -0.50 | -0.60 | -0.60 | -0.56 | ||||||
| EPS (Diluted) | -5.28 | 5.18 | -4.83 | -2.44 | -2.27 | -2.00 | -2.70 | -2.73 | -1.26 | -1.84 | -0.99 | -0.96 | -0.76 | -1.12 | -0.83 | -0.63 | -0.50 | -0.60 | -0.60 | -0.56 | ||||||
| Shares Outstanding | 2.98M | 2.82M | 3.00M | 3.00M | 3.01M | 3.00M | 3.01M | 3.10M | 8.38M | 5.06M | 10.27M | 11.28M | 13.58M | 12.20M | 12.95M | 16.06M | 16.69M | 15.31M | 18.21M | 19.24M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.98M | 2.82M | 3.00M | 3.00M | 3.01M | 3.00M | 3.01M | 3.10M | 8.38M | 5.06M | 10.27M | 11.28M | 13.58M | 12.20M | 12.95M | 16.06M | 16.69M | 15.31M | 18.21M | 19.24M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.99M | 3.00M | 3.00M | 3.01M | 3.01M | 3.01M | 3.01M | 3.10M | 8.38M | 5.06M | 10.22M | 10.26M | 13.58M | 11.03M | 12.95M | 16.26M | 17.26M | 17.80M | 18.64M | 21.90M | ||||||
| EBITDA | -15.76M | 14.63M | -14.48M | -6.23M | -5.77M | -5.96M | -7.80M | -7.78M | -10.77M | -9.39M | -10.24M | -10.92M | -10.34M | -13.48M | -10.74M | -10.09M | -8.04M | -8.84M | -10.60M | -10.43M | ||||||
| Interest ExpensesInt Expense | 1.07M | 1.08M | 0.09M | 0.34M | 0.71M | 0.00M | 0.00M | 0.04M | 0.05M | 0.14M | 0.23M | 0.18M | 0.19M | 0.43M | 0.34M | 0.41M | 0.41M |